NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 131-135

  Sabbagh, Nada ^a   Delaporte, Emmanuel ^a   Marez, Delphine ^a   Lo Guidice, Jean Marc ^a   Piette, Frederic ^a   Broly, Franck ^a  

^a UNIV LILLE   (France)

Author keywords

Chronic discoid lupus erythematosus; N acetylation polymorphism; NAT2; Sulfasalazine

Indexed keywords

ACYLTRANSFERASE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISCOID LUPUS ERYTHEMATOSUS; DRUG ACETYLATION; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACETYLATION; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SULFASALAZINE;

DISCOIDAE;

EID: 0030898186     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00006     Document Type: Article

References (24)

1. Bax DE, Greaves MS, Amos RS. Sulphasalazine for rheumatoid arthritis: relationship between dose. acetylator phenotype and response to treatment. Br J Rheumatol 1986: 25, 282-284
2. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991: 88, 5237-5241.
3. Carmichael AJ, Paul CJ. Discoid lupus erythematosus responsive to sulfasalazine. Br J Dermatol 1991: 125, 291
4. Carrol G. A comparative study of sulphasalazine and penicillamine in rheumatoid arthritis. Aust NZ J Med 1983: 13, 212-216.
5. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet: 57, 581-592.
6. Chalmers IM, Sitar D, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990: 17, 764-770.
7. Das KM, Eastwood MA. Acetylation polymorphism of sulphapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 1975: 18, 514-520.
8. Delaporte E, Piette F, Bourjot D, Duneton-Bitbol V, Bergoend H. Treatment of chronic lupus erythematosus with sulfasalazine. Press-Med 1994: 23, 95-96.
9. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992:43, 399-403.
10. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991: 42, 1007-1014.
11. Kitas GD, Farr M, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992: 21, 220-225.
12. Ladero JM, Jimenez LC, Fernandez MJ, Robledo A. Acetylator polymorphism in discoid lupus erythematosus. Eur J Clin Pharmacol 1988: 34, 307-308.
13. Meyer UA. Polymorphism of human acetyltransferases. Environ Health Perspect 1994: 6, 213-216.
14. Price Evans DA. N-acetyltransferase. In: Kalow W. eds. Pharmacogenetics of drug metabolism. New York: Pergamon Press. Inc., 1992: 95-178.
15. Pullar T, Capell HA. Variables affecting efficacy and toxicity of sulfasalazine in rheumatoid arthritis. Drugs 1986: 32 (Suppl.). 54-57.
16. Pullar T, Hunter JA, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulfasalazine in rheumatoid arthritis. Ann Rheum Dis 1985: 44, 831-837.
17. Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M. Relationship between the acetylator phenotype. plasma sulfapyridine and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Isr J Med Sci 1990: 26, 31-34.
18. Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995: 50, 137-156.
19. Ratain MJ, Mick R, Berezin F, Janish L, Schilsky RL, Vogelzang NJ, Brian Lane L. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993: 53, 2304-2308.
20. Sharp ME, Wallace SM, Hindmarsh KW, Brown MA. Acetylator phenotype and serum levels of sulphapyridine in patients with inflammatory bowel disease. Eur J Clin Pharmacol 1981: 21, 243-250.
21. Taggart AJ, McDermott BJ, Roberts SD. The effect of age and acetylator phenotype on the pharmacokinet of sulfasalasine in patients with rheumatoid arthritis. Clin Pharmacokinet 1992: 23, 311-320.
22. Vatsis KP, Weber WW, Bell DA, Dupret JM, Price Evans DA. Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5, 1-17.
23. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985: 37, 25-79.
24. Wolkenstein P, Carrière V, Charue D, Bastuji-Garin S, Revuz J, Roujeau J-C, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Steven-Johnson syndrome. Pharmacogenetics 1995: 5, 255-258.